Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | AR | P10275 | 3/20 | 0.46 |
| ▸ | LYN | P07948 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.43 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9422170 | 0.86 | SMN1; SMN2 (0.45) | ALDH1A1TDP1GAALMNAMEN1 | |
| SCHEMBL98477 | 0.82 | MAOB (0.50) | ALDH1A1GAAMEN1MAPTKMT2A | |
| SCHEMBL96225 | 0.82 | — | — | |
| SCHEMBL29398372 | 0.82 | ALDH1A1 (0.72) | ALDH1A1L3MBTL1HTTTDP1ACHE | |
| SCHEMBL456868 | 0.82 | ALDH1A1 (0.72) | ALDH1A1L3MBTL1HTTTDP1ACHE | |
| SCHEMBL29746015 | 0.82 | ALDH1A1 (0.72) | ALDH1A1L3MBTL1HTTTDP1ACHE | |
| SCHEMBL921045 | 0.81 | AR (0.65) | ALDH1A1L3MBTL1HTTTDP1ACHE | |
| SCHEMBL29377828 | 0.80 | ALDH1A1 (0.69) | ALDH1A1L3MBTL1HTTTDP1ACHE | |
| SCHEMBL1688852 | 0.80 | ALDH1A1 (0.69) | ALDH1A1L3MBTL1HTTTDP1ACHE | |
| SCHEMBL5216502 | 0.78 | MAOB (0.41) | ALDH1A1GAALMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1886377-A | Benzoylaminopyridinecarboxylic acid derivatives as Glucokinase (GLK) activators | ASTRAZENECA AB (SE) | 2006-12-27 | — | — | CN | claimed |
| EP-1301480-B1 | 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LAB (US) | 2007-09-12 | — | — | EP | disclosed |
| CN-1886377-A | Benzoylaminopyridinecarboxylic acid derivatives as Glucokinase (GLK) activators | ASTRAZENECA AB (SE) | 2006-12-27 | — | — | CN | disclosed |
| US-20050113435-A1 | Histamine-3 receptor ligands for diabetic conditions | HANCOCK ARTHUR A (US) | 2005-05-26 | — | — | US | disclosed |
| EP-1474132-A1 | HISTAMINE-3 RECEPTOR LIGANDS FOR DIABETIC CONDITIONS | Abbott Laboratories (US) | 2004-11-10 | — | — | EP | disclosed |
| EP-1467727-A1 | 1,3-DISUBSTITUTED AND 1,3,3,-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | Abbott Laboratories (US) | 2004-10-20 | — | — | EP | disclosed |
| US-6620839-B2 | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | ABBOTT LABORATORIES | 2003-09-16 | — | — | US | disclosed |
| US-20030153548-A1 | Histamine-3 receptor ligands for diabetic conditions | ABBOTT LABORATORIES | 2003-08-14 | — | — | US | disclosed |
| WO-2003059341-A1 | 1,3-DISUBSTITUTED AND 1,3,3,-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003059342-A1 | HISTAMINE-3 RECEPTOR LIGANDS FOR DIABETIC CONDITIONS | ABBOTT LABORATORIES (US) | 2003-07-24 | — | — | WO | disclosed |
| US-20030134835-A1 | Histamine-3 receptor ligands for diabetes conditions | ABBOTT LABORATORIES | 2003-07-17 | — | — | US | disclosed |
| EP-1301480-A1 | 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2003-04-16 | — | — | EP | disclosed |
| US-6515013-B2 | For diseases or conditions caused by or exacerbated by histamine-3 receptor activity | ABBOTT LABORATORIES | 2003-02-04 | — | — | US | disclosed |
| US-20020137931-A1 | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2002-09-26 | — | — | US | disclosed |
| US-20020035103-A1 | 1,3-Disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2002-03-21 | — | — | US | disclosed |
| WO-2002006223-A1 | 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137931-A1 | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH1 | ALDH1A1 962/4885L3MBTL1 4509/4885HTT 1422/4885 |
| US-20020035103-A1 | 1,3-Disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH1 | ALDH1A1 962/4885L3MBTL1 4509/4885HTT 1422/4885 |
| US-20030153548-A1 | Histamine-3 receptor ligands for diabetic conditions | HRH4, HRH2, HRH3 | ALDH1A1 1508/4885L3MBTL1 4796/4885HTT 2520/4885 |
| US-20050113435-A1 | Histamine-3 receptor ligands for diabetic conditions | HRH4, HRH2, HRH3 | ALDH1A1 1508/4885L3MBTL1 4796/4885HTT 2520/4885 |
| US-20030134835-A1 | Histamine-3 receptor ligands for diabetes conditions | HRH4, HRH2, HRH3 | ALDH1A1 1597/4885L3MBTL1 4778/4885HTT 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.